Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.

SecuritySKYS / Sky Solar Holdings, Ltd. (83084J103)
Institutional Owners8
Institutional Shares98,675,951
Institutional Value$ 38,030,000 USD

Institutional Stock Ownership and Shareholders()

Sky Solar Holdings, Ltd. (NASDAQ:SKYS) has 8 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 98,675,951 shares. Largest shareholders include IDG-Accel China Capital Associates L.P., Invesco Ltd., Permal Asset Management Llc, Hsbc Holdings Plc, Hsbc Holdings Plc, Millennium Management Llc, Susquehanna International Group, Llp, Citadel Advisors Llc, and UBS Group AG.
Sky Solar Holdings, Ltd. (NASDAQ:SKYS) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2017-08-14 13F-HR PERMAL ASSET MANAGEMENT LLC 531,846 531,846 0.00 1,085 798 -26.45
2018-08-14 13F-HR MILLENNIUM MANAGEMENT LLC 0 20,901 0 24
2018-05-11 13F-HR HSBC HOLDINGS PLC 41,666 50
2018-08-14 13F-HR UBS Group AG 7,889 6,565 -16.78 10 8 -20.00
2018-08-14 13F-HR Invesco Ltd. 461,688 539,268 16.80 559 631 12.88
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 19,882 23
2016-11-14 13F-HR IDG-Accel China Capital Associates L.P. 97,453,914 97,453,914 0.00 35,449 36,423 2.75
2018-08-10 13F-HR HSBC HOLDINGS PLC 41,666 41,666 0.00 50 49 -2.00
2018-04-25 13F-HR QUENTEC ASSET MANAGEMENT LLC 490,327 0 -100.00 735 0 -100.00
2018-08-14 13F-HR Entrustpermal Partners Offshore Lp 28,980 0 -100.00 36 0 -100.00

Related Articles

REPH: Recro Pharma Analysis and Research Report

12h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

13h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

13h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="

Silicon Investor Message Boards

This table lists all message boards related to SKYS / Sky Solar Holdings, Ltd. on message board site Silicon Investor.

SKATA - Skysat Comm Network Corp SKATA - Skysat Comm Network Corp SKATA - Skysat Comm Network Corp
CUSIP: 83084J103